Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

Item

http://www.wikidata.org/entity/Q43264870

Q43264870

about

Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.

P2860

Q30661022-2989269D-7B89-45D6-BCE6-03B4319C7F2C Q34593746-37B7EEF8-6840-47C4-8C53-0C7464FCE88D Q36848102-38353C3B-F7E8-421C-A2EB-0B8718B7A429 Q43060768-280AF1EA-77A1-4E45-B7A2-1360636B96BF Q47158989-C8E88CB5-5DD5-40CF-9B2C-C94CA6F2C793

P2860

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

Item

http://www.wikidata.org/entity/Q43264870

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@en

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@nl

type

Item

label

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@en

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@nl

prefLabel

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@en

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@nl

P1476

Preoperative weekly cisplatin, ...... (SICOG) randomised trial 9908.

@en

P2093

C Siani

http://www.w3.org/2001/XMLSchema#string

G Comella

http://www.w3.org/2001/XMLSchema#string

G D'Aiuto

http://www.w3.org/2001/XMLSchema#string

G Frasci

http://www.w3.org/2001/XMLSchema#string

G Iodice

http://www.w3.org/2001/XMLSchema#string

I Capasso

http://www.w3.org/2001/XMLSchema#string

L Vizioli

http://www.w3.org/2001/XMLSchema#string

M D'Aiuto

http://www.w3.org/2001/XMLSchema#string

M Di Bonito

http://www.w3.org/2001/XMLSchema#string

M Montella

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.

Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.

Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

P304

707-716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP356

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Petrillo

P577

2009-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26881629

http://www.w3.org/2001/XMLSchema#string

P698

19815652

http://www.w3.org/2001/XMLSchema#string

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

about

P2860

P2860

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698